Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma

Leukemia and Lymphoma

Volumn 50, Issue 11, 2009, Pages 1860-1864

  Brown, Ross D ^a   Spencer, Andrew ^b   Joy Ho, Phoebe ^a   Kennedy, Nola ^b   Kabani, Karieshma ^a   Yang, Shihong ^a   Sze, Daniel M ^a   Aklilu, Esther ^a   Gibson, John ^a   Joshua, Douglas E ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b ALFRED HOSPITAL   (Australia)

Author keywords

Clones; Multiple myeloma; Prognosis; T cell; Thalidomide

Indexed keywords

PREDNISONE; THALIDOMIDE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; HUMAN; LYMPHOCYTE ACTIVATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE MYELOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE;

CLONE CELLS; COMBINED MODALITY THERAPY; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE COUNT; MULTIPLE MYELOMA; PROGNOSIS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 71049147113     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903216804     Document Type: Article

References (20)

1. Raje N, Anderson K. Thalidomide - a revival story. New Engl J Med 1999;341:1606-1609.
2. Parman T, Wiley MJ, Wells PG. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med 1999;5:582-585.
3. Uchiyama H, Barut BA, Mohrbacher AF, et al. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993;82:3712-3720.
4. Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 1996;87:1104-1112.
5. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: Increasing evidence for a multistep transformation process. Blood 1998;91:3-21.
6. Damiano JS, Cress AE, Hazlehurst LA, et al. Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999;93:1658-1667.
7. Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996;31:213-221.
8. Jakob C, Sterz J, Zavrski I, et al. Angiogenesis in multiple myeloma. Eur J Cancer 2006;42:1581-1590.
9. Field EO, Gibbs JE, Tucker DF, et al. Effect of thalidomide on the graft versus host reaction. Nature 1996;211:1308-1310.
10. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. New Engl J Med 1992;326:1055-1058.
11. Haslett PA, Corral LG, Albert M, et al. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8p subset. J Exp Med 1998;187:1885-1892.
12. Hayashi T, Hideshima T, Akiyama M, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: Clinical application. Br J Haematol 2005;128:192-203.
13. LeBlanc R, Hideshima T, Catley LP, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004;103:1787-1790.
14. Galustian C, Meyer B, Labarthe M-C, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009;58:1033-1045.
15. Brown RD, Yuen E, Nelson M, et al. The prognostic significance of T cell receptor b gene rearrangements and idiotype-reactive T cells in multiple myeloma. Leukemia 1997;11:1313-1317.
16. Raitakari M, Brown RD, Gibson J, et al. T cells in myeloma. Hematol Oncol 2003;21:33-42.
17. Sze DM-Y, Brown RD, Yuen E, et al. Clonal cytotoxic T cells in myeloma. Leuk Lymphoma 2003;44:1667-1674.
18. Spencer A, Prince M, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009;27:1788-1793.
19. Liu W, Putnam AL, Xu-yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4p Tregs. J Exp Med 2006;203:1701-1711.
20. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cytotoxicity in multiple myeloma. Blood 2001;98:210-216. .